A case study of salami slicing: Pooled analyses of duloxetine for depression

Psychotherapy and Psychosomatics

Volumn 79, Issue 2, 2010, Pages 97-106

  Spielmans, Glen I ^a   Biehn, Tracey L ^a   Sawrey, Dustin L ^a  

^a METROPOLITAN STATE UNIVERSITY   (United States)

Author keywords

Depression; Duloxetine; Pooled analysis; Salami slicing, duplicate publication

Indexed keywords

DULOXETINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; EDITOR; ETHNICITY; HUMAN; HYPOMANIA; MEDICAL LITERATURE; NAUSEA; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; SEXUAL DYSFUNCTION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; URINARY TRACT DISEASE;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DEPRESSIVE DISORDER, MAJOR; DRUG INDUSTRY; HUMANS; META-ANALYSIS AS TOPIC; PUBLISHING; THIOPHENES; TREATMENT OUTCOME;

EID: 73249124411     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000270917     Document Type: Article

References (81)

1. Brochard L, Brun-Buisson C: Salami publication: a frequent practice affecting readers' conf idence. Intensive Care Med 2007; 33: 212-213.
2. Hoit JD: Salami science. Am J Speech Lang Pathol 2007; 16:94.
3. Johnson C: Repetitive, duplicate, and redundant publications: a review for authors and readers. J Manipulative Physiol Ther 2006; 29:505-509.
4. Baggs JG: Issues and rules for authors concerning authorship versus acknowledgements, dual publication, self plagiarism, and salami publishing. Res Nurs Health 2008; 31: 295-297.
5. Britton J, Knox AJ: Duplicate publication, redundant publication, and disclosure of closely related publications. Thorax 1999; 54:378.
6. Norman I, Griffiths P: Duplicate publication and 'salami slicing': ethical issues and practi-ca l solutions. Int J Nurs Stud 2008; 45: 1257-1260.
7. Moffatt B, Elliott C: Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2007; 50: 18-31.
8. Eli Lilly: 2001 integrated product plan: Zy-prexa product team. http://www.furioussea-sons.com /z y prex a%20doc u ment s/ ZY201249534.pdf.
9. PeerView, Inc: About PeerView, Inc. 2005. http://epeerview.com/general/ about.html.
10. Villarroel EP: Master plan: the making of a successful publication strategy. Pharma-voice 2007; 3:1-5.
11. Bailey BJ: Duplicate publication in the field of otolaryngology-head and neck surgery. Oto-lar yngol Head Neck Surg 20 02; 126: 211-216.
12. Durani P: Duplicate publications: redundancy in plastic surgery literature. J Plast Re-constr Aesthet Surg 2006; 59:975-977.
13. Schein M, Paladugu R: Redundant surgical publications: tip of the iceberg? Surgery 2001; 129: 655-661.
14. von Elm E, Poglia G, Walder B, Tramèr MR: Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA 20 04; 291: 974-980.
15. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B: Evidence b(i)ased medicine-Selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326: 1171-1173.
16. Spielmans GI: Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008; 77: 1 2-16.
17. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 20 05; 14 3: 415-4 26.
18. Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M: Immediate switching of antidepressant therapy: results from a clinical trial of dulox-etine. Ann Clin Psychiatry 2005; 17: 259-268.
19. Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M: An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005; 25: 552-560.
20. Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM: Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006; 98:437-447.
21. Lewis-Fernández R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM: Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority Caucasian patients. J Clin Psychiatry 2006; 67: 1379-1390.
22. Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG: Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006; 94:183-189.
23. Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE: Duloxetine efficacy for major depressive disorder in male versus female patients: data from 7 randomized, double-blind, placebo-controlled tri-a ls. J Clin Psychiat r y 2006; 67: 761-770.
24. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25:132-140.
25. Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F: An evaluat ion of t he ca rdiova scula r safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30: 437-455.
26. Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG: Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006; 8:269-278.
27. Acharya N, Rosen AS, Polzer JP, D'Souza DN, Perahia DG, Cavazzoni PA, Baldessari-ni RJ: Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psycho-pharmacol 2006; 26: 587-594.
28. Perahia DG, Kajdasz DK, Desaiah D, Had-dad PM: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Dis-ord 2005; 89:207-212.
29. Dunner DL. D'Souza DN, Kajdasz DK, Det ke MJ, Russell JM: Is treatment-associated hy-pomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005; 87:115-119.
30. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ: Sexual functioning assessed in 4 double-blind placebo-and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66: 686-692.
31. Viktrup L, Pangallo BA, Detke MJ, Zinner NR: Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry 2004; 6:65-73.
32. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J: Incidence and duration of antidepressant-induced nausea: du-loxetine compared with paroxetine and f luoxetine. Clin Ther 2004; 26: 14 4 6-14 5 5.
33. Nelson JC, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Watkin JG, Kennedy JS: Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005; 13:227-235.
34. Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE: Dulox-etine for the treatment of major depressive disorder in women ages 40 to 55 years. Psy-chosomatics 20 05; 46: 345-354.
35. Bech P, Kajdasz DK, Porsdal V: Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006; 188:273-280.
36. Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ: Use of effect size to determine optimal dose of du-loxetine in major depressive disorder. J Psy-chiatr Res 2007; 41: 3 1 1-3 1 8.
37. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM: Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 337-34 8.
38. Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ: Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 2007; 22: 348-355.
39. Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007; 618:1337-1348.
40. Perahia DG, Kajdasz DK, Royer MG, Walker DJ, Raskin J: Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Int Clin Psychophar-macol 2006; 21:285-295.
41. Mallinckrodt CH, Watkin JG, Liu C, Wohl-reich MM, Raskin J: Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychia-tr y 2005; 5: 1.
42. Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Ty lee A: Duloxet i ne 60 mg once dai ly i n t he treatment of milder major depressive disorder. Int J Clin Pract 2006; 60:613-620.
43. Cookson J, Gilaberte I, Desaiah D, Kajdasz DK: Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharma-col 2006; 21:267-273.
44. Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ: Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005; 21:170-177.
45. Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD: Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005; 39: 161-17 2.
46. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ: Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18:53-61.
47. Beebe FA: Publication planning. Med Mark Media 2004; 39: 40-46.
48. Fava GA: The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. Psychother Psychosom 2009; 78: 220-227.
49. Jureidini JN, McHenry LB: Key opinion leaders and paediatric antidepressant over-prescribing. Psychother Psychosom 20 09; 78: 197-201.
50. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-399.
51. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-39 0.
52. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psy-chiatr Res 2005; 39:43-53.
53. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatr y 2002; 63: 308-315.
54. Goldstein DJ, Mallinckrodt C, Lu Y, Demi-track MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63:225-231.
55. Ballesteros J, Callado LF, Gutierrez M: An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol 20 07; 27: 219-221.
56. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ: Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Psychiatr y 2006; 21: 367-378.
57. Detke MJ, Wiltse CG, Mallinckrodt CH, Mc-Namara RK, Demitrack MA, Bitter I: Dulox-etine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsy-chopharmacol 20 04; 14: 457-470.
58. Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J: The safety and tolerabil-ity of duloxetine in depressed elderly patients with and without medical comorbidi-ty. Int J Clin Pract 2007; 61:1283-1293.
59. Eckert L, Lançon C: Duloxetine compared with f luoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006; 6:30.
60. Fava M, Mallinckrodt CH, Detke MJ, Wat-kin JG, Wohlreich MM: The effect of dulox-etine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatr y 2004; 65: 521-530.
61. Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM: The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry 2007; 19:187-195.
62. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L: A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007; 23: 175-18 4.
63. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of dulox-etine on painful physical symptoms associated with depression. Psychosomatics 2004; 45: 17-2 8.
64. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychophar-macol 2005; 20: 32 7-3 41.
65. Khan A, Schwartz K: Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports. Ann Clin Psychiatry 2007; 19:31-36.
66. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003; 5: 19-28.
67. Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ: The efficacy of dulox-etine: a comprehensive summary of results from MMRM and LOCF-ANCOVA in eight clinical trials. BMC Psychiatry 2004; 4:26.
68. Mallinckrodt CH, Meyers AL, Prakash A, Faries DE, Detke MJ: Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull 2007; 40: 101-114.
69. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC: Efficacy of du-loxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 16 4: 900-909.
70. Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM: Du-loxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007; 23:1303-1318.
71. Nelson C, Pritchett YL, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ: The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatr y 2006; 8: 212-219.
72. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME: A randomized, double-blind comparison of du-loxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008; 42:22-34.
73. Raskin J, Xu JY, Kajdasz DK: Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. Int Psychogeriatr 2008; 20: 309-327.
74. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus esci-talopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401-416.
75. Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Hom-berger CH, Mischou lon D, Fava M: T he combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006; 23: 17 8-181.
76. van Baardewijk M, Vis PM, Einarson TR: Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin 2005; 21: 1271-1279.
77. Vis PM, van Baardewijk M, Einarson TR: Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005; 39:1798-1807.
78. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006; 188:346-353.
79. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237-124 4
80. Eli Lilly Study 4091a Summary. http://www. clinicalst udy resu lts.org /d r ugde t a i ls/ ?unique-id=4091a&sort=c.company- name&page=1&drug- id=170
81. Eli Lilly Study 3327b Summary. http://www. cl i n ic a lst udy resu lts.org /d r ugde t a i ls/ ?unique-id=3327b&sort=c.company- name&page=1&drug-id=138